A- A A+

Linkage to care specialist facilitates access to hepatitis C treatment for people who inject drugs

A prospective, longitudinal study involving more than 1,000 people who inject drugs has identified a promising role for linkage to care specialists in facilitating rapid access to hepatitis C treatment. The study, which was conducted in Texas, USA, ensured that individuals newly diagnosed with hepatitis C were contacted by a linkage to care specialist within 48 hours of being referred to the service, thereby ensuring that almost 50% of patients referred to a medical practitioner made it to their first appointment and that 60% of those seen were initiated on treatment.

(European Association for the Study of the Liver, 12.04.2018)


Infektiologen entwickeln therapeutischen Impfstoff gegen Hepatitis B

Braunschweig – Einen neuen therapeutischen Impfstoff gegen eine Hepatitis-B-Infektion haben Wissenschaftler am Deutschen Zentrum für Infektionsforschung (DZIF) in Braunschweig entwickelt. Dieser soll nun in die klinische Prüfung gehen. Obwohl es einen wirksamen Impfstoff gegen Hepatitis B gibt, leiden weltweit rund 260 Millionen Menschen unter einer chronischen Hepatitis B, die derzeit nicht heilbar ist. Jedes Jahr sterben etwa 880.000 Menschen an den Folgen der Infektion. (aerzteblatt.de, 12.04.2018)


Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals.

Schietroma I, Scheri GC, Pinacchio C, Statzu M, Petruzziello A, Vullo V.

Open Virol J. 2018 Feb 28;12:16-25. doi: 10.2174/1874357901812010016.


Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

Grebely, Jason et al.

The Lancet Gastroenterology & Hepatology , Volume 3 , Issue 3 , 153 - 161



Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?

Butt AS, Sharif F, Abid S.

World J Hepatol. 2018 Feb 27;10(2):267-276. doi: 10.4254/wjh.v10.i2.267. Review.


Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting.

Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, Pfeiffer-Vornkahl H, Berg T, Sarrazin C, Hüppe D, Manns MP, Mauss S.

United European Gastroenterol J. 2018 Mar;6(2):213-224. doi: 10.1177/2050640617716607.


Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3.

Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium.

United European Gastroenterol J. 2018 Mar;6(2):225-237. doi: 10.1177/2050640617717158.


Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.

Smolders EJ, Smit C, de Kanter C, Dofferhoff A, Arends JE, Brinkman K, Rijnders B, van der Valk M, Reiss P, Burger DM; ATHENA National HIV Observational Cohort.

HIV Med. 2018 Mar;19(3):216-226. doi: 10.1111/hiv.12570.


Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis.

Buonomo AR, Zappulo E, Scotto R, Pinchera B, Perruolo G, Formisano P, Borgia G, Gentile I.

Int J Infect Dis. 2017 Oct;63:23-29. doi: 10.1016/j.ijid.2017.07.026.


Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.

Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J.

World J Gastroenterol. 2018 Mar 28;24(12):1361-1372. doi: 10.3748/wjg.v24.i12.1361.


Sofosbuvir and daclatasvir.

Hessel MH, Cohen AF, Rissmann R.

Br J Clin Pharmacol. 2016 Sep;82(3):878-9. doi: 10.1111/bcp.13011.


Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.

Rupp C, Hippchen T, Neuberger M, Sauer P, Pfeiffenberger J, Stremmel W, Gotthardt DN, Mehrabi A, Weiss KH.

World J Gastroenterol. 2018 Mar 28;24(12):1353-1360. doi: 10.3748/wjg.v24.i12.1353.


Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/HCV-coinfected patients.

Merchante N, Rodríguez-Arrondo F, Revollo B, Merino E, Ibarra S, Galindo MJ, Montero M, García-Deltoro M, Rivero-Juárez A, Téllez F, Delgado-Fernández M, Ríos-Villegas MJ, García MA, Vera-Méndez FJ, Ojeda-Burgos G, López-Ruz MA, Metola L, Omar M, Alemán-Valls MR, Aguirrebengoa K, Portu J, Raffo M, Macías J, Pineda JA; GEHEP-002 Study Group.

AIDS. 2018 Mar 28. doi: 10.1097/QAD.0000000000001809.



Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.

Des Jarlais DC, Cooper HLF, Arasteh K, Feelemyer J, McKnight C, Ross Z (2018)

PLoS ONE 13(3): e0194799. https://doi.org/10.1371/journal.pone.0194799


Hepatitis C: Test, Treat, Cure...Now! (Video)

It is now over two years since there has been a 95% effective cure for hepatitis C - one tablet a day for three months with almost zero side effects.

One wonders if those at greatest risk of catching hepatitis C were people who eat more than 3 steaks a month, how many of the 150 million with the virus would have already received treatment?

Is it not time for HCV and harm reduction to receive greater prominence at the biennial International AIDS conference? (IDHDP – International Doctors for Healthier Drug Policies, 01.05.2017, Video, 01:25)


Intervention Packages to Reduce the Impact of HIV and HCV Infections Among People Who Inject Drugs in Eastern Europe and Central Asia: A Modeling and Cost-effectiveness Study.

Mabileau G, Scutelniciuc O, Tsereteli M, Konorazov I, Yelizaryeva A, Popovici S, Saifuddin K, Losina E, Manova M, Saldanha V, Malkin JE, Yazdanpanah Y.

Open Forum Infect Dis. 2018 Feb 17;5(3):ofy040. doi: 10.1093/ofid/ofy040.


Hepatitis C in Injection-Drug Users - A Hidden Danger of the Opioid Epidemic.

Liang TJ, Ward JW.

N Engl J Med. 2018 Mar 29;378(13):1169-1171. doi: 10.1056/NEJMp1716871.


Activity of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in sera of patients with hepatitis C.

Jelski W, Strumnik A, Orywal K, Lapinski TW, Swiderska M, Szmitkowski M.

Arch Med Sci. 2018 Mar;14(2):281-287. doi: 10.5114/aoms.2016.60406.


The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.

Ti L, Socías ME, Wood E, Milloy M-J, Nosova E, DeBeck K, et al. (2018)

PLoS ONE 13(3): e0194162. doi.org/10.1371/journal.pone.0194162


Transmission genetics of drug-resistant hepatitis C virus.

van Buuren N, Tellinghuisen TL, Richardson CC, Kirkegaard K.

Elife. 2018 Mar 28;7. pii: e32579. doi: 10.7554/eLife.32579.


Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.

Schackman BR, Gutkind S, Morgan JR, Leff JA, Behrends CN, Delucchi KL, McKnight C, Perlman DC, Masson CL, Linas BP.

Drug Alcohol Depend. 2018 Feb 13. pii: S0376-8716(18)30025-5. doi: 10.1016/j.drugalcdep.2017.11.031.



Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C.

Yeh ML, Huang CI, Huang CF, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Kuo HT, Dai CY, Yu ML, Chuang WL.

Oncotarget. 2018 Jan 13;9(15):12240-12249. doi: 10.18632/oncotarget.24219.


Decreasing HIV, Syphilis, and Hepatitis C Infection After a Decade of Harm Reduction Implementation Among Drug Users in Southwestern Areas of China.

Chen Y, Tang Z, Tang S, Shen Z, Zhu Q, Li R, Huang W, Huang Y, Liang F, Wang L, Chen H, Ruan Y, Shao Y, Tsuei SH, Lan G.

J Stud Alcohol Drugs. 2018 Mar;79(2):248-257.



Access to Hepatitis C treatment: lessons from implementation of strategies for increasing access to antiretroviral treatment.

Assefa Y, Hill PS, Williams OD.

Int J Infect Dis. 2018 Mar 14. pii: S1201-9712(18)30063-8. doi: 10.1016/j.ijid.2018.03.004.


Deutschland. Ausgaben für Hepatitis-C-Medikamente gesunken

Berlin – Die Ausgaben für Arzneimittel gegen Hepatitis C sind in den vergangenen Jahren deutlich gesunken. Darauf hat Zentralinstitut für die kassenärztliche Versorgung in Deutschland (Zi) hingewiesen. Demnach lagen die Bruttoverordnungskosten im 4. Quartal 2017 bei rund 126 Millionen Euro, im ersten Quartal 2015 waren es noch mehr als 400 Millionen Euro. (aerzteblatt.de, 27.03.2018)


Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma.

Petruzziello A.

Open Virol J. 2018 Feb 28;12:26-32. doi: 10.2174/1874357901812010026.